Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer

PURPOSE: Cetuximab demonstrates improved efficacy outcomes in patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS exon 2. Resistance to cetuximab is mediated by activating less frequent mutations in the RAS genes beyond KRAS exon 2. We performed extended RAS Mutational analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dalyong, Hong, Yong Sang, Kim, Jeong Eun, Kim, Kyu-pyo, Lee, Jae-Lyun, Chun, Sung-Min, Kim, Jihun, Jang, Se Jin, Kim, Tae Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266405/
https://www.ncbi.nlm.nih.gov/pubmed/27121720
http://dx.doi.org/10.4143/crt.2016.069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266405/
https://www.ncbi.nlm.nih.gov/pubmed/27121720
http://dx.doi.org/10.4143/crt.2016.069

Ejemplares similares